Dupont Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Dupont Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-315	Closed	-$109K	–	1401
2020 Q2	$109K	Buy	315 +16	+5%	+$4.99K	﹤0.01%	1256
2020 Q1	$80K	Buy	+299	New	+$92.5K	﹤0.01%	1209
2018 Q4	–	Sell	-114	Closed	-$105K	–	1201
2018 Q3	$105K	Hold	114	–	–	﹤0.01%	927
2018 Q2	$84K	Sell	114 -911	-89%	-$1.05M	﹤0.01%	953
2018 Q1	$1.63M	Buy	+1,025	New	+$1.32M	0.04%	387

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dupont Capital Management's NKTR Position: Q3 2020 in Review

Dupont Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 315 shares — an estimated $109K sold.

Dupont Capital Management first reported a position in NKTR in Q1 2018 and held it in 5 quarters. The position peaked at $1.63M in Q1 2018. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

Dupont Capital Management reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
Dupont Capital Management sold 315 Nektar Therapeutics shares in Q3 2020, an estimated $109K.
Dupont Capital Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 5 quarters.
Dupont Capital Management's Nektar Therapeutics position peaked at $1.63M in Q1 2018.
249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Dupont Capital Management's 13F filing for Q3 2020, filed 29 Oct 2020.